Advanced Therapeutic
Nuclear Medicine Solutions
Advanced therapeutic radiopharmaceutical products supporting targeted radionuclide therapy, thyroid treatment, neuroendocrine tumor applications, and precision oncology solutions.
Advanced Radionuclide Therapy
ACTINIUM-225
Alpha-emitting radionuclide supplied as a solution in hydrochloric acid intended for peptide precursor labelling.
- DOTA-TOC for neuroendocrine tumors
- ITG-PSMA-1 for prostate cancer treatment
- DOTA-Zoledronic acid for bone metastasis
- Chemical purity > 99.9%
ITRAPOL
Yttrium-90 precursor solution intended for radiolabelling of medicinal products specifically developed for therapeutic radionuclide applications.
- Yttrium-90 chloride solution
- Radiolabelling applications
- Glass vial in shielding lead container
- Calibration: 3 days
Therapeutic Product Portfolio
Sodium iodide Na131I Diagnostic Capsules
Diagnostic radioisotope capsules for thyroid function disorders, thyroid tissue evaluation, and metastatic differentiated thyroid cancer diagnostics.
Sodium Iodide Na131I Therapeutic Capsules
Therapeutic capsules indicated for hyperthyroidism, Graves-Basedow disease, thyroid residue ablation, and iodine-accumulating metastases.
Sodium Iodine Na131I Solution
Therapeutic sodium iodide injection solution for thyroid carcinoma, thyroid metastases, and hyperthyroidism treatment.
MIBG-131I Diagnostic Solution
Diagnostic solution for localization, staging, and treatment monitoring of neuroendocrine tumors.
MIBG-131I Therapeutic Solution
Therapeutic radiopharmaceutical solution used for tumors capable of retaining iobenguane, including neuroblastomas and pheochromocytomas.
LU-177 n.c.a
High-purity no-carrier-added Lutetium-177 with excellent radiolabeling performance and long shelf-life up to two weeks.
Peptide & Theranostic Solutions
DOTATATE AA 0.1 mg
Direct radiolabelling kit developed for preparation of 90Y or 177Lu-DOTATATE without purification procedures.
- Radiolabelling efficiency > 98%
- Sterile freeze-dried formulation
- Optimized for Lu177 & Y90
- 12 months shelf life
DOTATATE AA 0.25 mg
Advanced peptide kit for therapeutic radionuclide radiolabelling applications with high radiochemical stability.
- Direct therapeutic radiolabelling
- High radiochemical stability
- Freeze-dried sterile composition
- Theranostic oncology support
PSMA-D4 100 μg
Specialized PSMA peptide intended for 177Lu labelling in targeted prostate cancer applications.
- Targeted PSMA applications
- 177Lu therapeutic labelling
- Sterile freeze-dried peptide
- 12 months expiry date